Sánchez Calero, Janet and Young, Louise C. and Marrero Faz, Evangelina and L. Harvey, Alan (2014) Efecto inhibitorio de un extracto acuoso de las hojas de Allophylus cominia (L.) Sw sobre las proteínas tirosina fosfatasa 1B y dipeptidil peptidasa IV. Revista Cubana de Farmacia, 48 (4). pp. 672-683. ISSN 1561-2988 ,

This version is available at https://strathprints.strath.ac.uk/57822/

Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.uk

The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the management and persistent access to Strathclyde’s intellectual output.
Inhibitory effect of *Allophylus cominia* (L.) Sw leaves aqueous extract on tyrosine phosphatase 1B and dipeptidyl peptidase IV proteins

Efector inhibitorio de un extracto acuoso de las hojas de *Allophylus cominia* (L.) Sw sobre las proteínas tirosina fosfatasa 1B y dipeptidil peptidasa IV

DraC. Janet Sánchez Calero, I Lic. Louise C. Young, II DrC. Evangelina Marrero Faz, I Ph.D Alan L Harvey II

I National Centre for Animal and Plant Health (CENSA), San José de las Lajas, Mayabeque, Cuba.
II Strathclyde Institute for Pharmaceutical and Biomedical Sciences (SIPBS) / University of Strathclyde, Glasgow, Scotland, United Kingdom.

ABSTRACT

**Introduction:** *Allophylus cominia* (L.) Sw is a Cuban medicinal plant used by traditional medicine for the treatment of diabetes with unknown mechanisms of action.

**Objective:** to evaluate the effect of *Allophylus cominia* (L.) Sw leaves aqueous extract and its fractions on protein tyrosine phosphatase 1B (PTP1B) and dipeptidyl peptidase IV (DPPIV) enzymatic activity, as therapeutic targets of type 2 diabetes.

**Methods:** the aqueous extract of *A. cominia* leaves was successively partitioned with organic solvents mixtures, thus increasing polarity in order to obtain ten fractions. The extract and its fractions were tested for their possible antidiabetic activity on therapeutic targets of type 2 diabetes: PTP1B and DPPIV. The enzymatic inhibition assays were performed and the inhibitory activity was calculated with the fluorescence values using an excitation wavelength of 360 nm and an emission wavelength of 460 nm.

**Results:** the aqueous extract from *A. cominia* inhibited the enzymatic activity of PTP1B and DPPIV according to the concentration, being IC$_{50}$ values equal to 0.69 µg/mL and 344.3 µg/mL, respectively. Several fractions were detected as potent PTP1B inhibitors. The most polar fractions AcF9 and AcF10 were more active, showing IC$_{50}$ values of 4.4 µg/mL and 3.8 µg/mL respectively. The fractions
showed a slight DPPIV inhibition, being fractions AcF6, AcF9 and AcF10 the most active, exhibiting inhibition percentages of 52.0 %, 39.0 % and 40.0 % respectively.

Conclusions: *A. cominia* aqueous extract and its polar fractions (AcF9 and AcF10) have antidiabetic properties in vitro and are promissory candidates for development of new drugs with inhibitory activity of PTP1B and DPPIV for type 2 diabetes treatment.

Keywords: *Allophylus cominia* (L.) Sw, antidiabetic activity, PTP1B inhibitors, DPPIV inhibitors, type 2 diabetes therapeutic targets.

RESUMEN

**Introducción:** *Allophylus cominia* (L.) Sw es una planta medicinal cubana usada por la medicina tradicional para el tratamiento de la diabetes, cuyo mecanismo de acción es desconocido.

**Objetivo:** evaluar el efecto del extracto acuoso de hojas de *A. cominia* (L.) Sw y sus fracciones sobre la proteína tirosina fosfatasa 1B (PTP1B) y dipeptidil peptidasa IV (DPPIV) como diana terapéuticas para el tratamiento de la diabetes tipo 2.

**Métodos:** el extracto acuoso de hojas de *A. cominia* fue fraccionado sucesivamente con mezclas de solventes orgánicos, incrementando la polaridad, para obtener diez fracciones. El extracto y sus fracciones fueron evaluados para su posible actividad antidiabética sobre diana terapéuticas de diabetes tipo 2: PTP1B y DPPIV. Se realizaron ensayos de inhibición enzimática y la actividad inhibitoria se calculó a partir de los valores de fluorescencia, empleando longitudes de onda de excitación y de emisión de 360 nm y 460 nm respectivamente.

**Resultados:** el extracto acuoso de *A. cominia* inhibió la actividad enzimática de PTP1B y DPPIV de manera dependiente de la concentración, con valores de CI\(_{50}\) de 0,69 µg/mL y 344,3 µg/mL respectivamente. Varias fracciones se detectaron como potentes inhibidores de PTP1B. Las fracciones más polares AcF9 y AcF10 fueron las más activas, y mostraron valores de CI\(_{50}\) de 4,4 µg/mL y 3,8 µg/mL respectivamente. Las fracciones mostraron una ligera inhibición de DPPIV, y las más activas resultaron AcF6, AcF9 y AcF10, con valores de porcentajes de inhibición de 52,0 %, 39,0 % y 40,0 % respectivamente.

**Conclusiones:** el extracto acuoso de *A. cominia* y sus fracciones polares (AcF9 y AcF10) tienen propiedades antidiabéticas in vitro y son candidatos promisorios para el desarrollo de nuevos medicamentos con actividad inhibitora de PTP1B y DPPIV para el tratamiento de la diabetes tipo 2.

**Palabras clave:** *Allophylus cominia* (L.) Sw, actividad antidiabética, inhibidores de PTP1B, inhibidores de DPPIV, diana terapéuticas de diabetes tipo 2.

INTRODUCTION

Diabetes mellitus is a metabolic disorder of multiple etiologies characterized by chronic hyperglycemia and altered metabolism of lipids, carbohydrates and proteins, due to defects in insulin secretion and/or insulin action.\(^1\)

http://scielo.sld.cu
Protein tyrosine phosphatase 1B (PTP1B) has been implicated in the negative regulation of insulin signaling by dephosphorylating the insulin receptor (IR) as well as its substrate, insulin receptor substrate-1 (IRS-1) and insulin receptor substrate-2 (IRS-2), and selective inhibition of PTP1B has emerged as a potential drug target for the treatment of type 2 diabetes.²

Dipeptidyl peptidase IV (DPP-IV) is a serine protease, which causes breakdown of the peptides that containing proline or alanine as the second residue. The most important substrate for this enzyme are incretin hormones such as: glucagon-like peptide 1 (GLP-1) and glucose-dependent insulino tropic polypeptide (GIP), which are released into the intestine in response to nutrient ingestion and stimulate insulin secretion induced by glucose.³ Thus, GLP-1 stimulates insulin biosynthesis and secretion, reduces glucagon release, slows gastric emptying, reduces appetite and stimulates the regeneration and differentiation of Langerhans islets of β cells.⁴ Moreover, GIP is involved in glucose metabolism by increasing insulin secretion.⁵ Both peptides have short half-lives due to rapid degradation by protease DPP-IV. DPP-IV inhibitors are a new class of oral anti-hyperglycemic agents, whose effect is mediated through the incretin hormones. Thus, the inhibition of DPP-IV enzymatic activity, prolongs the action of GLP-1 and GIP, which maintain glucose homeostasis. Hence, DPP-IV inhibition has the potential to be a novel, efficient and tolerable approach to treat type 2 diabetes.⁶

Allophylus cominia (L.) Sw (Sapindaceae), also known as Rhus cominia (L.) or Schmiedelia cominia Sw, which common name is palo de caja, caja or caja común, is one of the most well-known medicinal plant in Cuba.⁷ It was initially used as a remedy against gastrointestinal disorders, but was subsequently employed as a remedy for diabetes. It has also been reported in the use of tuberculosis and catarrhal diseases in general. In addition, medicinal properties against toothache and use as a blood purifier in venereal diseases have also been attributed to this plant.⁷

Several investigations have reported the hypoglycaemic activity of A. cominia aqueous extracts in normoglycaemic and type 1 diabetic animals models.⁸-¹⁰ The phytochemical studies of the aqueous extract of leaves from A. cominia revealed the presence of tannins, free amines, phenols, triterpenes and steroids. In addition, in this extract proteins, carbohydrates such as arabinose, xylose, galactose, glucose and fatty acids (lauric, miristic, palmitic, estearic and arachidonic) were identified.¹¹

The aim of the study was to investigate the inhibitory effect on PTP1B and DPP-IV of A cominia leaves (aqueous extract and its fractions) as the underlying mechanism to the potential type 2 anti-diabetic properties of this plant.

**METHODS**

**PLANT MATERIAL**

*Allophylus cominia* (L.) Sw (Sapindaceae) leaves were collected from forest of Cotilla (San José de Las Lajas, Mayabeque, Cuba) in the month of February (2008). Plants were taxonomically authenticated by Prof. Fernando Franco Flores, in the Laboratory of Botany at the Agriculture University of Havana, Cuba. A voucher specimen of the plant is kept for reference (HFA-1769) in the Herbarium of this institution.
PLANT EXTRACT

Fresh leaves of *A. cominia* were dried in a stove at 37 °C for 96 h. The dry leaves were milled in fine particles of 5 mm. The plant extract was obtained from powder aqueous extraction at 95 °C for 30 min, in a 10 % (w/v) relation. The resulting extract was freeze dried. Dry extract was stored in plastic bottles in a desiccator for future experiments.

FRACTIONATION OF PLANT EXTRACT

Ten fractions were obtained from *A. cominia* aqueous extract using a Flash Chromatography System. It was used 5 g of dried extract in adsorption chromatography employing a column (Isolute Flash, Si, 100 g) and as mobile phase, an organic solvents mixture, from low to high polarity (n-hexane; 1,2 di-chloro-metane; 2-butanol; methanol and water). Elution was achieved using solvent gradients of 400 mL aliquots of n-hexane 100 % (AcF1), 1,2 di-chloro-metane 100 % (AcF2), 1,2 di-chloro-metane 75 %; 2-butanol 25 % (AcF3), 1,2 di-chloro-metane 50 %: 2-butanol 50 % (AcF4), 1,2 di-chloro-metane 25 %; 2-butanol 75 % (AcF5), 2-butanol 100 % (AcF6), 2-butanol 75 %: methanol 25 % (AcF7), 2-butanol 50 %: methanol 50 % (AcF8), 2-butanol 25 %: methanol 75 % (AcF9) and methanol 50 %: water 50 % (AcF10).

PROTEIN TYROSINE PHOSPHATASE 1B (PTP1B) ENZYME ASSAY

The assay was performed as previously described, in 96-well black microplates. PTP1B (human, recombinant, Sigma) was incubated in the presence and absence of *A. cominia* extract and its fractions.

For inhibition assay, 25 L of different concentrations of *A. cominia* aqueous extract and its fractions (0.01-300 µg/mL), the standard inhibitor [Bis(4-Trifluoromethylsulphonamidophenyl)-1,4-diisopropylbenzene] (TFMS, Calbiochem) (0.1-300 µM) or buffer solution (pH 7.2), containing the following reagents at final concentrations indicated: Hepes (25 mM), sodium chloride (50 mM), Dithiothreitol (2 mM), ethylene-diamine-tetraacetic acid (EDTA) (2.5 mM) and Bovine Serum Albumin (BSA) (0.01 mg/mL), were pre-incubated with 50 µL of enzyme for 30 min at 37 °C. Subsequently, 25 µL of substrate (6.8-difluoro-4-methylumbelliferyl phosphate) (DiFMUP, Invitrogen Ltd.), at a final concentration of 10 µM, was added to the reaction mixture and was placed in a 37 °C incubator for 10 min. The amount of end product (umbelliferone) obtained was measured by determining change in fluorescence on a Wallac Victor 2 (Perkin-Elmer, Sunnyvale, CA) using an excitation wavelength of 360 nm and an emission wavelength of 460 nm.

DIPEPTIDYL PEPTIDASE IV (DPPIV) ENZYME ASSAY

The assay was performed as previously described, in black 96-well microtitre plates. DPPIV (human, recombinant, Sigma) was incubated in the presence and absence of *A. cominia* extract and its fraction.

For inhibition assays, 25 µL of different concentrations of aqueous extract from *A. cominia* (0.01-300 µg/mL) and its fractions (100 µg/mL), the standard inhibitor [(3N-[(2S, 3S)-2-amino-3-methyl-pentanoyl]-1,3-thiazolidine) hemifumarate] (P32/98) (0.1-300 µM) or buffer solution (pH 8.00), containing the following chemicals at final concentrations
concentrations indicated: Tris-HCl (100 mM) with Bovine Serum Albumin (BSA) (0.1 mg/mL), were preincubated with 50 µL of enzyme (final concentration: 0.3 nM) for 30 min at 37 °C. After 25 mL of substrate [Gly-Pro-7-amido-4-methylcoumarin hydrobromide] (Gly-pro-AMC), at final concentration of 30 µM, was added to reaction mixture and it was placed in a 37 °C incubator for 30 min. The amount of end product (umbelliferone) obtained was estimated by measuring change in fluorescence on a Wallac Victor 2 (Perkin-Elmer, Sunnyvale, CA) using an excitation wavelength of 355 nm and an emission wavelength of 460 nm.

The percentage inhibition of PTP1B and DPP IV was calculated as follows: [Enzyme in the presence of compound (random fluorescent units)/Enzyme in the absence of compound (random fluorescent units)]*100.

STATISTICAL ANALYSIS

The IC<sub>50</sub> value for each compound was calculated by non-linear regression analysis using GraphPad Prism version 4.03 -2005 (La Jolla, California, USA) subsequently, the apparent Ki of the substrate was calculated for each sample using the Cheng-Prusoff equation. All the values were expressed as mean ± standard error of mean (SE) for 4 replicates of the experiments.

Conflict of interest

The authors have no conflict of interest to declare.

RESULTS

*A. cominia* aqueous extract inhibited the enzymatic activity of PTP1B in a concentration dependent manner. The mean inhibitory concentration (IC<sub>50</sub>) values was 0.69 µg/mL (Ki 0.26 (± 0.025 µg/mL) (Fig. 1).

---

**Fig. 1.** Dose-response curve of *A. cominia* aqueous extract effect on PTP1B enzymatic activity expressed as percent of control (100 %). Values represent mean ± SE for each concentration tested.
Ten fractions from the *A. cominia* aqueous extract were screened against PTP1B; seven were identified as possible PTP1B inhibitors. Figure 2 shows that when tested at a concentration of 100 µg/mL (n= 3), fraction 1 appeared to have no effect on the activity of this enzyme, fractions 2 and 3 showed only a small inhibition of PTP1B activity. Fractions 4, 7 and 8 exhibited a moderate inhibition of this protein, whereas fractions 5, 6, 9 and 10 showing the most apparent potent effect on PTP1B inhibition. The percentages of inhibition values in decreasing order: F9 (90.7 %), F6 (89.3 %), F10 (88.7 %), F5 (84.0 %), F7 (72.9 %), F4 (72.7 %), F8 (68.3 %), F2 (40.0 %), F3 (33.0 %).

Figure 3 (A, B, C, D, E and F) shows dose-response curves of the more active fractions, obtained from the aqueous extract of *A. cominia* leaves, on enzymatic activity of PTP1B. The graphs show that PTP1B inhibitory activity increased in a dependent manner of the fractions concentration, reaching inhibition values close to 100 % at the maximum concentration tested (300 µg/mL). Differences were found in the IC₅₀ values among different fractions. The more active fractions, AcF9 and AcF10, appeared to be related to increasing polarity, which gave IC₅₀ values of 4.4 µg/mL and 3.8 µg/mL (Ki 1.7 and 1.4 µg/mL) respectively.

*A. cominia* aqueous extract inhibited the enzymatic activity of DPPIV in a concentration dependent manner, reaching 50 % percentage of inhibition values around the highest concentration tested of 300 µg/mL (Fig. 4).

Figure 5 shows that fractions 6, 9 and 10 exhibited moderate inhibition of DPPIV activity, resulting fraction 6 the most active fraction in this assay; while the other fractions showed a slight inhibition of this protein. The percentage of inhibition values in decreasing order were: F6 (52.0 %), F10 (40.0 %), F9 (39.0 %), F7 (32.0 %), F8 (31.0 %), F5 (26.0 %), F3 (25.0 %), F4 (23.0 %), F1 (18.0 %), F2 (17.0 %).
Fig. 3. Dose response curves of active fractions AcF4 (A), AcF5 (B), AcF6 (C), AcF8 (D), AcF9 (E) and AcF10 (F) from A. corinna leaves aqueous extract on PTP1B enzymatic activity expressed as percent of control (%). Values represent mean ± SE for each concentration tested.
Fig. 4. Dose response curve of A. cominia aqueous extract effect on DPPIV enzymatic activity expressed as percent of control (100%). Values represent mean ± SE for each concentration tested.

Fig. 5. Screening of fractions from A. cominia aqueous extract as DPPIV inhibitors. Values are expressed as a percentage of enzymatic activity of control (100 %). Values represent mean ± SE for each fraction tested (n= 4).
DISCUSSION

The PTP1B and DPPIV inhibition assays were used in the present study to elucidate the type 2 antidiabetic mechanism of action of the *A. cominia* aqueous extract.

In line with the present research, other plant extracts have shown inhibitory effect on PTP1B enzymatic activity in the same range of concentrations as the *A. cominia* aqueous extract. Thus, the methanolic extract of *Psidium guajava* displayed a significant inhibitory effect of 87 % against PTP1B at a concentration of 30 µg/mL. Other authors have reported that the methanolic extract of dried roots of *Salvia miltiorrhiza* exhibited a significant inhibitory effect on the activity of this enzyme.

The differences in the polarity of the solvents used in the mobile phase during fractionation process of *A. cominia* extract tends to bring out varieties of compounds in the diverse fractions. Hence, the inhibitory activity on PTP1B across the fractions indicates that different types of compounds are able to act as inhibitors of this enzyme.

It has also been previously reported that PTP1B can be inhibited by different types of secondary metabolites from plants. A study reported that several types of compounds isolated from the plant *Ardisia japonica*: oleanolic acid, quercitrin and norbergenin showed a moderate inhibitory activity on this enzyme. Other authors have reported that three diterpene compounds obtained from methanolic extract of dried roots of *Salvia miltiorrhiza* as responsible for this effect which exhibited noncompetitive inhibition of PTP1B activity with IC\textsubscript{50} values of 11.4 ± 0.6 mM, 22.4 ± 0.6 mM and 56.1 ± 6.3 mM, respectively. Additional work found that triterpenes isolated from the methanol extract of *Diospyros kaki* (Persimmon) leaves had an inhibitory effect on the activity of PTP1B enzyme with IC\textsubscript{50} values in the range of 3.1 ± 0.2 to 18.8 ± 1.3 mM. It was also reported that a proteoglycan obtained from the fruit of *Ganoderma lucidum*, showed efficient PTP1B inhibitory potency with an IC\textsubscript{50} value of 5.12 ± 0.05 µg/mL.

The fraction 6 (butanolic fraction) from *A. cominia* resulted one of the more active fraction in the PTP1B inhibition. This result correspond with data refered in other papers, which informed that the butanolic fraction from methanolic extract of *Psidium guajava* containing the active entity with an IC\textsubscript{50} value of 2.6 µg/mL. Unpublished studies demonstrated recently the AcF6 contains flavonoids, which are the secondary metabolites responsible of the PTP1B inhibition. Thus, quercitrin and norbergenin isolated from *Ardisia japonica* showed a moderate inhibitory activity on this enzyme with IC\textsubscript{50} values of 24 µM and 28 µM respectively.

The fractions 9 and 10 were the most active fractions in this assay. Unpublished results about chemical characterization of them indicated that contained tannins, which was previously demonstrated for *A. cominia* aqueous extract, although further experiments are necessary in order to dilucidated their chemical structure. Other authors confirm the importance of tannins in the PTP1B inhibitory effect, comparing results of total methanolic extract and detannificated extract of *Cichorium intybus*, demonstrated that tannins are responsible component of this pharmacological effect.

Previous studies have shown that PTP1B enzyme has two active sites: a catalytic site and an allosteric site. X-ray diffraction has identified the interactions between PTP1B and allosteric inhibitors. A general mechanism proposed for other proteins tyrosine phosphatases is that allosteric inhibitors prevent the formation of the enzymes active form, blocking the WPD loop mobility in the catalytic site, which closure is essential for catalytic activity of the enzyme. *Hansen, et al.*, 2005 reported that the allosteric
inhibition of PTP1B activity can be achieved by selective modification of cysteine residues, Cys 121, which although not located in the catalytic site, providing interactions with residues which are in contact with the His 214, which has been shown to be important for catalysis. Thus, the amentoflavone obtained from Selaginella tamariscina, a biflavonoide, inhibited PTP1B activity by allosteric inhibition. Further work to determine whether the potentially active fractions of A. cominia are working at the catalytic or an allosteric site.

Consistent with the results in this study, many other papers have reported inhibition of DPPIV enzymatic activity by plant extracts: the aqueous extract from Cistus incanus L. leaves, the methanolic extract of Mangifera indica leaves, the aqueous extracts of plants native of Armenia which cited cloves, cinnamon, green and black tea being highly effective, blackberry leaves, melilot, oregano and seabuckthorn which behaved as inhibitors of this enzyme, in combination with other antidiabetic drugs. In addition, the hexane extract of Annona squamosa inhibited DPP-IV at 30 mg/mL.

DPP-IV is a 766-amino acid transmembrane glycoprotein consisting of three parts, a cytoplasmic tail, a trans-membrane region and an extracellular part. The extracellular part is divided into a catalytic domain and an eight-bladed β-propeller domain. The latter contributes to the inhibitor binding site which consists of a deep lipophilic pocket combined with several exposed aromatic side chains achieving high affinity for small molecule binding. DPP-IV inhibitors usually have an electrophilic group that can interact with the hydroxyl of the catalytic serine in the active binding site. DPP-IV inhibitors without the electrophilic group have shown toxicity due to affinity to other dipeptidyl peptidases, such as: DPP-2, DPP-8 and DPP-9.

The secondary metabolites responsible of the DPPIV inhibition may be the flavonoids present in the A. cominia aqueous extract which existence was recently demonstrated in unpublished studies. This type of compound probably is present in the most active fraction (AcF6), but further experiments are necessary for confirmation it. Thus, an article describes the antidiabetic effect of the flavonoid rich fraction of Pilea microphylla (L.) inhibited dipeptidyl peptidase IV (DPP-IV) in vitro with an IC₅₀ = 520.4 ± 15.4 μg/mL.

Further studies will be necessary in order to corroborate these effects on in vivo models of type 2 diabetes. Also it will be important to approach toxicological studies of the active fractions in order to demonstrate the safety of them.

CONCLUSION

In our in vitro research, A. cominia aqueous extract, in particular its polar fractions (AcF9 and AcF10) have promissory antidiabetic properties mediated by PTP1B and DPPIV, relevant therapeutic targets for type 2 diabetes.

Acknowledgements

This work was supported by an Academic Link from British Council and an IFS research project No. F/4906-1.
REFERENCES


